{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:34:11Z","timestamp":1789133651576,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"DOI":"10.7759\/cureus.51705","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T16:14:42Z","timestamp":1704471282000},"source":"Crossref","is-referenced-by-count":34,"title":["Alzheimer\u2019s Disease: The Past, Present, and Future of a Globally Progressive Disease"],"prefix":"10.7759","author":[{"given":"Bhuvanasai","family":"Vejandla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohith","family":"Appalaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rithik S","family":"Veeravalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Sravya","family":"Gude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Alzheimer\u2019s disease: a brief history of immunotherapies targeting amyloid \u03b2","volume":"15","author":"Vogt ACS","year":"2023","unstructured":"Vogt ACS, Jennings GT, Mohsen MO, Vogel M, Bachmann MF. Alzheimer\u2019s disease: a brief history of immunotherapies targeting amyloid \u03b2. Int J Mol Sci. 2023, 15:3895.","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000369101","article-title":"Amyloid-beta: a crucial factor in Alzheimer's disease","volume":"24","author":"Sadigh-Eteghad S","year":"2015","unstructured":"Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J. Amyloid-beta: a crucial factor in Alzheimer's disease. Med Princ Pract. 2015, 24:1-10. 10.1159\/000369101","journal-title":"Med Princ Pract"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2022.89236","article-title":"The economic and societal burden of Alzheimer disease: managed care considerations","volume":"28","author":"Skaria AP","year":"2022","unstructured":"Skaria AP. The economic and societal burden of Alzheimer disease: managed care considerations. Am J Manag Care. 2022, 28:S188-96. 10.37765\/ajmc.2022.89236","journal-title":"Am J Manag Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.07.222","article-title":"Vascular dysfunction-the disregarded partner of Alzheimer's disease","volume":"15","author":"Sweeney MD","year":"2019","unstructured":"Sweeney MD, Montagne A, Sagare AP, et al.. Vascular dysfunction-the disregarded partner of Alzheimer's disease. Alzheimers Dement. 2019, 15:158-67. 10.1016\/j.jalz.2018.07.222","journal-title":"Alzheimers Dement"},{"key":"ref5","article-title":"Prions and prion-like pathogens in neurodegenerative disorders","volume":"18","author":"Peggion C","year":"2014","unstructured":"Peggion C, Sorgato MC, Bertoli A. Prions and prion-like pathogens in neurodegenerative disorders. Pathogens. 2014, 18:149-63.","journal-title":"Pathogens"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040778","article-title":"Type 2 diabetes mellitus as a risk factor for Alzheimer\u2019s disease: review and meta-analysis","volume":"10","author":"Athanasaki A","year":"2022","unstructured":"Athanasaki A, Melanis K, Tsantzali I, et al.. Type 2 diabetes mellitus as a risk factor for Alzheimer\u2019s disease: review and meta-analysis. Biomedicines. 2022, 10:778. 10.3390\/biomedicines10040778","journal-title":"Biomedicines"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X18666200807130637","article-title":"Neurodegenerative pathways in Alzheimer\u2019s disease: a review","volume":"19","author":"Ramachandran AK","year":"2021","unstructured":"Ramachandran AK, Das S, Joseph A, Shenoy GG, Alex AT, Mudgal J. Neurodegenerative pathways in Alzheimer\u2019s disease: a review. Curr Neuropharmacol. 2021, 19:679-92. 10.2174\/1570159X18666200807130637","journal-title":"Curr Neuropharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.155","article-title":"Tau-based therapies in neurodegeneration: opportunities and challenges","volume":"16","author":"Li C","year":"2017","unstructured":"Li C, G\u00f6tz J. Tau-based therapies in neurodegeneration: opportunities and challenges. Nat Rev Drug Discov. 2017, 16:863-83. 10.1038\/nrd.2017.155","journal-title":"Nat Rev Drug Discov"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon EE","year":"2018","unstructured":"Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018, 14:399-415. 10.1038\/s41582-018-0013-z","journal-title":"Nat Rev Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108609","article-title":"On the relationships between epilepsy, sleep, and Alzheimer's disease: a narrative review","volume":"129","author":"Hanke JM","year":"2022","unstructured":"Hanke JM, Schindler KA, Seiler A. On the relationships between epilepsy, sleep, and Alzheimer's disease: a narrative review. Epilepsy Behav. 2022, 129:108609. 10.1016\/j.yebeh.2022.108609","journal-title":"Epilepsy Behav"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101464","article-title":"Autophagy in Alzheimer's disease pathogenesis: therapeutic potential and future perspectives","volume":"72","author":"Zhang Z","year":"2021","unstructured":"Zhang Z, Yang X, Song YQ, Tu J. Autophagy in Alzheimer's disease pathogenesis: therapeutic potential and future perspectives. Ageing Res Rev. 2021, 72:101464. 10.1016\/j.arr.2021.101464","journal-title":"Ageing Res Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/0891988710383571","article-title":"Genetics of Alzheimer disease","volume":"23","author":"Bekris LM","year":"2010","unstructured":"Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010, 23:213-27. 10.1177\/0891988710383571","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00146","article-title":"Modifiable risk factors for Alzheimer\u2019s disease","volume":"11","author":"Edwards Iii GA","year":"2019","unstructured":"Edwards Iii GA, Gamez N, Escobedo G Jr, Calderon O, Moreno-Gonzalez I. Modifiable risk factors for Alzheimer\u2019s disease. Front Aging Neurosci. 2019, 11:146. 10.3389\/fnagi.2019.00146","journal-title":"Front Aging Neurosci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302368","article-title":"Trial of the MIND diet for prevention of cognitive decline in older persons","volume":"389","author":"Barnes LL","year":"2023","unstructured":"Barnes LL, Dhana K, Liu X, et al.. Trial of the MIND diet for prevention of cognitive decline in older persons. N Engl J Med. 2023, 389:602-11. 10.1056\/NEJMoa2302368","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1053942","article-title":"Sleep deficiency promotes Alzheimer's disease development and progression","volume":"13","author":"Lv YN","year":"2022","unstructured":"Lv YN, Cui Y, Zhang B, Huang SM. Sleep deficiency promotes Alzheimer's disease development and progression. Front Neurol. 2022, 13:1053942. 10.3389\/fneur.2022.1053942","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-014-0470-z","article-title":"Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies","volume":"16","author":"Borisovskaya A","year":"2014","unstructured":"Borisovskaya A, Pascualy M, Borson S. Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies. Curr Psychiatry Rep. 2014, 16:470. 10.1007\/s11920-014-0470-z","journal-title":"Curr Psychiatry Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/1179573520907397","article-title":"Current and future treatments in Alzheimer disease: an update","volume":"12","author":"Yiannopoulou KG","year":"2020","unstructured":"Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer disease: an update. J Cent Nerv Syst Dis. 2020, 12:1179573520907397. 10.1177\/1179573520907397","journal-title":"J Cent Nerv Syst Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2012.672559","article-title":"Amyloid beta (A\u03b2) peptide modulators and other current treatment strategies for Alzheimer's disease (AD)","volume":"17","author":"Lukiw WJ","year":"2012","unstructured":"Lukiw WJ. Amyloid beta (A\u03b2) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). Expert Opin Emerg Drugs. 2012, 17:43-60. 10.1517\/14728214.2012.672559","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref19","article-title":"Alzheimer disease: pharmacologic and nonpharmacologic therapies for cognitive and functional symptoms","volume":"15","author":"Epperly T","year":"2017","unstructured":"Epperly T, Dunay MA, Boice JL. Alzheimer disease: pharmacologic and nonpharmacologic therapies for cognitive and functional symptoms. Am Fam Phys. 2017, 15:771-8.","journal-title":"Am Fam Phys"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2705146","article-title":"Impact of new drugs for therapeutic intervention in Alzheimer\u2019s disease","volume":"27","author":"Olloquequi J","year":"2022","unstructured":"Olloquequi J, Ettcheto M, Cano A, et al.. Impact of new drugs for therapeutic intervention in Alzheimer\u2019s disease. Front Biosci (Landmark Ed). 2022, 27:146. 10.31083\/j.fbl2705146","journal-title":"Front Biosci (Landmark Ed)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04134.x","article-title":"New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs","volume":"73","author":"Salomone S","year":"2012","unstructured":"Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol. 2012, 73:504-17. 10.1111\/j.1365-2125.2011.04134.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer\u2019s disease: pitfalls and promise","volume":"83","author":"van Dyck CH","year":"2018","unstructured":"van Dyck CH. Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer\u2019s disease: pitfalls and promise. Biol Psychiatry. 2018, 83:311-9. 10.1016\/j.biopsych.2017.08.010","journal-title":"Biol Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101496","article-title":"Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer's disease: a systematic review","volume":"72","author":"Jeremic D","year":"2021","unstructured":"Jeremic D, Jim\u00e9nez-D\u00edaz L, Navarro-L\u00f3pez JD. Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer's disease: a systematic review. Ageing Res Rev. 2021, 72:101496. 10.1016\/j.arr.2021.101496","journal-title":"Ageing Res Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck CH","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al.. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023, 388:9-21. 10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims JR","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al.. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023, 330:512-27. 10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy","volume":"9","author":"Barakos J","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, et al.. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis. 2022, 9:211-20. 10.14283\/jpad.2022.21","journal-title":"J Prev Alzheimers Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00637-0","article-title":"Anti-amyloid therapies for Alzheimer disease: finally, good news for patients","volume":"18","author":"Ramanan VK","year":"2023","unstructured":"Ramanan VK, Day GS. Anti-amyloid therapies for Alzheimer disease: finally, good news for patients. Mol Neurodegener. 2023, 18:42. 10.1186\/s13024-023-00637-0","journal-title":"Mol Neurodegener"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2003.12.004","article-title":"Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge","volume":"25","author":"Citron M","year":"2004","unstructured":"Citron M. Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. Trends Pharmacol Sci. 2004, 25:92-7. 10.1016\/j.tips.2003.12.004","journal-title":"Trends Pharmacol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00662-x","article-title":"Repurposed agents in the Alzheimer\u2019s disease drug development pipeline","volume":"12","author":"Bauzon J","year":"2020","unstructured":"Bauzon J, Lee G, Cummings J. Repurposed agents in the Alzheimer\u2019s disease drug development pipeline. Alzheimers Res Ther. 2020, 12:98. 10.1186\/s13195-020-00662-x","journal-title":"Alzheimers Res Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.667874","article-title":"Repurposing of anti-diabetic agents as a new opportunity to alleviate cognitive impairment in neurodegenerative and neuropsychiatric disorders","volume":"12","author":"Chen Q","year":"2021","unstructured":"Chen Q, Cao T, Li N, et al.. Repurposing of anti-diabetic agents as a new opportunity to alleviate cognitive impairment in neurodegenerative and neuropsychiatric disorders. Front Pharmacol. 2021, 12:667874. 10.3389\/fphar.2021.667874","journal-title":"Front Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1034243","article-title":"Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China","volume":"13","author":"Cao Y","year":"2022","unstructured":"Cao Y, Yu F, Lyu Y, Lu X. Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China. Front Neurol. 2022, 13:1034243. 10.3389\/fneur.2022.1034243","journal-title":"Front Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/182967-alzheimers-disease-the-past-present-and-future-of-a-globally-progressive-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:16:05Z","timestamp":1707509765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/182967-alzheimers-disease-the-past-present-and-future-of-a-globally-progressive-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.51705","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,5]]}}}